文献速递妇科产科

IOTA简易规则、SRR评估、ADNEX模型与O-RADS在北美女性附件病变良恶性鉴别中的性能比较

Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-04-08

单中心诊断准确性研究纳入150例附件病变女性,前瞻性应用ADNEX模型、回顾性应用IOTA简易规则(SR)、SRR评估和O-RADS,比较术前鉴别良恶性的性能。恶性病变中ADNEX和SRR的平均恶性风险均显著高于良性,ADNEX的AUC为0.937、SRR为0.941。以恶性风险≥10%为阈值,ADNEX敏感性97.5%、特异性63.6%,SRR敏感性100%、特异性51.8%,O-RADS敏感性100%、特异性46.4%;SR可应用的113例中敏感性100%、特异性95.6%。

要点

  • ADNEX与SRR在北美人群中鉴别附件良恶性的AUC分别为0.937和0.941。
  • 以10%为阈值,IOTA模型敏感性接近或达100%,特异性高于O-RADS。
  • SR可应用病例特异性达95.6%,不确定病例归为恶性则特异性降至79.1%。

核心结论

  • 在北美女性中应用IOTA术语和技术时,IOTA模型性能与已发表的其他人群结果一致。
  • IOTA SR、SRR、ADNEX与O-RADS术前鉴别附件肿瘤良恶性的敏感性相似,但IOTA模型特异性更高。
  • IOTA算法不需要使用磁共振成像。

研究设计与样本

  • 单中心诊断准确性研究,2018年3月至2021年2月纳入150例附件病变女性。
  • ADNEX模型前瞻性分类,SR、SRR评估和O-RADS回顾性应用。
  • 超声检查后6个月内行手术及组织学分析。

主要发现

  • 150例中良性110例(73.3%)、恶性40例(26.7%)。
  • 恶性 vs 良性病变的平均恶性风险:ADNEX(不含CA125)为63.3% vs 11.8%,SRR为74.1% vs 15.9%。
  • ADNEX的AUC为0.937,SRR的AUC为0.941。
  • O-RADS分类:2类17例(11.3%)、3类34例(22.7%)、4类66例(44.0%)、5类33例(22.0%)。
  • 2类和3类无组织学证实的恶性病变,4类有14例恶性、5类有26例恶性。

关键数值与推荐

  • 以恶性风险≥10%为阈值(区分O-RADS≤3类与4-5类),ADNEX敏感性97.5%(95%CI 85.3%-99.9%)、特异性63.6%(95%CI 53.9%-72.4%)。
  • 同阈值下SRR敏感性100%(95%CI 89.1%-100%)、特异性51.8%(95%CI 42.1%-61.4%)。
  • SR可应用的113例中,敏感性100%(95%CI 81.5%-100%)、特异性95.6%(95%CI 88.5%-98.6%)。
  • SR不确定的37例若归为恶性,敏感性仍100%,特异性降至79.1%(95%CI 70.1%-86.0%)。
  • O-RADS以≥10%为阈值,敏感性100%(95%CI 89.1%-100.0%)、特异性46.4%(95%CI 36.9%-56.1%)。

临床怎么用

  • 在北美人群中可应用IOTA SR、SRR和ADNEX模型进行附件病变术前良恶性鉴别。
  • IOTA模型较O-RADS特异性更高,且不需要磁共振成像。
  • SR可应用时特异性高,但需注意不确定病例的处理对特异性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), the IOTA Simple Rules risk assessment (SRR), the IOTA Assessment of Different NEoplasias in the adneXa (ADNEX) model and the Ovarian-Adnexal Reporting and Data System (O-RADS) in the same cohort of North American patients and to compare their performance in preoperative discrimination between benign and malignant adnexal lesions. METHODS: This was a single-center diagnostic accuracy study, performed between March 2018 and February 2021, which included 150 women with an adnexal lesion. Using the ADNEX model, lesions were classified prospectively, whereas the SR, SRR assessment and O-RADS were applied retrospectively. Surgery with histological analysis was performed within 6 months of the ultrasound exam. Sensitivity and specificity were determined for each testing modality and the performance of the different modalities was compared. RESULTS: Of the 150 women, 110 (73.3%) had a benign ovarian tumor and 40 (26.7%) had a malignant tumor. The mean risk of malignancy generated by the ADNEX model without CA 125 was significantly higher in malignant vs benign lesions (63.3% vs 11.8%) and the area under the receiver-operating-characteristics curve (AUC) of the ADNEX model for differentiating between benign and malignant adnexal masses at the time of ultrasound examination was 0.937. The mean risk of malignancy generated by SRR assessment was also significantly higher in malignant vs benign lesions (74.1% vs 15.9%) and the AUC was 0.941. To compare the ADNEX model, SRR assessment and O-RADS, the malignancy risk threshold was set at ≥ 10%. This cut-off differentiates O-RADS low-risk categories (Category ≤ 3) from intermediate-to-high-risk categories (Categories 4 and 5). At this cut-off, the sensitivity of the ADNEX model was 97.5% (95% CI, 85.3%-99.9%) and the specificity was 63.6% (95% CI, 53.9%-72.4%), and, for the SRR model, the sensitivity was 100% (95% CI, 89.1%-100%) and the specificity was 51.8% (95% CI, 42.1%-61.4%). In the 113 cases to which the SR could be applied, the sensitivity was 100% (95% CI, 81.5%-100%) and the specificity was 95.6% (95% CI, 88.5%-98.6%). If the remaining 37 cases, which were inconclusive under SR, were designated 'malignant', the sensitivity remained at 100% but the specificity was reduced to 79.1% (95% CI, 70.1%-86.0%). The 150 cases fell into the following O-RADS categories: 17 (11.3%) lesions in Category 2, 34 (22.7%) in Category 3, 66 (44.0%) in Category 4 and 33 (22.0%) in Category 5. There were no histologically proven malignant lesions in Category 2 or 3. There were 14 malignant lesions in Category 4 and 26 in Category 5. The sensitivity of O-RADS using a malignancy risk threshold of ≥ 10% was 100% (95% CI, 89.1%-100.0%) and the specificity was 46.4% (95% CI, 36.9%-56.1%). CONCLUSIONS: When IOTA terms and techniques are used, the performance of IOTA models in a North American patient population is in line with published IOTA results in other populations. The IOTA SR, SRR assessment and ADNEX model and O-RADS have similar sensitivity in the preoperative discrimination of malignant from benign pelvic tumors; however, the IOTA models have higher specificity and the algorithm does not require the use of magnetic resonance imaging. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hiett AK, Sonek JD, Guy M, et al. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women. Ultrasound Obstet Gynecol. 2022. PMID: 34533862. doi:10.1002/uog.24777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。